Related Experiment Video
Updated: May 15, 2026

Assays for the Degradation of Misfolded Proteins in Cells
Published on: August 28, 2016
Protein misfolding in disease and small molecule therapies
1Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal. gomes@itqb.unl.pt
Abstract:
A large number of human disorders are caused by defects in protein folding resulting from genetic mutations or adverse physiological conditions, and these are collectively referred to protein misfolding diseases. Such disorders imply dysfunction of a cellular process either as a result of a toxic gain of function due to protein aggregation, or loss of function due to protein instability, inefficient folding or defective trafficking. For a number of cases, drugs acting directly on the affected protein have been found to prevent misfolding and rescue function. This brief review will illustrate molecular mechanisms through which small molecules acting as folding correctors can prevent excessive protein buildup or recover faulty protein conformers, thus acting as effective therapeutic pharmacological chaperones. As background, the principles underlying the thermodynamics and kinetics of the protein folding reaction will be overviewed, as well as pathways leading to the formation of misfolding. The mechanism of action of small molecule correctors will then be discussed in light of these basic principles using illustrative examples referring to drugs that are effective over proteins involved in trafficking and folding diseases, amyloid aggregation disorders and metabolic deficiencies. An outlook on synergistic effects between different folding correctors and their combination with proteostasis regulators will also be addressed, as a relevant strategy towards the design of more effective therapies against protein folding diseases.
Insights
Small molecules can act as pharmacological chaperones to correct protein misfolding diseases. These folding correctors prevent protein buildup and restore function, offering a therapeutic strategy for various genetic disorders.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Protein misfolding diseases arise from genetic mutations or physiological stress, leading to cellular dysfunction via toxic gain-of-function (aggregation) or loss-of-function (instability, misfolding, defective trafficking).
- Therapeutic strategies can target the affected protein directly to prevent misfolding and restore normal function.
Purpose of the Study:
- To review the molecular mechanisms of small molecules acting as folding correctors in protein misfolding diseases.
- To illustrate how these molecules function as pharmacological chaperones to prevent protein aggregation or restore protein conformation.
Main Methods:
- Overview of protein folding thermodynamics, kinetics, and misfolding pathways.
- Discussion of small molecule corrector mechanisms of action with examples.
- Exploration of synergistic effects and combination therapies.
Main Results:
- Small molecules can act as therapeutic pharmacological chaperones by correcting protein folding.
- These agents can prevent excessive protein buildup or restore faulty protein conformers.
- Illustrative examples include drugs targeting trafficking, folding, amyloid, and metabolic diseases.
Conclusions:
- Small molecule folding correctors offer a promising therapeutic approach for protein misfolding diseases.
- Combining folding correctors with proteostasis regulators may enhance therapeutic efficacy.
- Further research into synergistic strategies is crucial for developing advanced treatments.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
The...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...

